MediBloc in Korea Raises $3.5M Investment; IMM Investment Leads Series A Round
MediBloc in Korea, a leading global healthcare company, announced that it has successfully attracted 4 billion won (approx. $3.5 million) of Series A investment from leading domestic investors and companies.
MediBloc in Korea attracted investments from financial investors such as IMM Investment, Company K Partners, and Naver D2SF, a strategic investment institution, in this round. This will allow close cooperation not only within the existing healthcare field but also with Naver, a leading Korean IT company, and is expected to raise the competitiveness of the MediBloc platform to the next level. This investment is significant in that it was made during a time when the global investment market has contracted considerably due to fallout from the COVID-19 pandemic. With this investment, MediBloc in Korea plans to start its long-term goals in earnest in order to form a more complete and individual-centered healthcare platform. The institutions participating in this investment boast a diverse portfolio of representative unicorns, including Coupang and Woowa Brothers, Krafton (formerly Blue Hole), RIDI Books, Watcha, and Musinsa.
IMM directorMoon Yeo-jeong, who led this investment, said, “In the post-COVID-19 era, we have a lot of interest and expectation for the growth of digital healthcare services in society as a whole. The high level of completeness and rapid growth rate of the healthcare platform developed and operated by MediBloc also had a great influence on the investment decision. I expect it to be.”
Dr. Allen Wookyun Kho, a co-founder of MediBloc in Korea, explained, “MediBloc in Korea is creating a ‘healthcare ecosystem’ that will innovate in every aspect of healthcare. We are very pleased to be recognized internally and externally for MediBloc’s technology and growth potential through this investment attraction. MediBloc in Korea will continue to do its best to create medical innovation based on medical data.”
Medipass, operated by MediBloc in Korea, is a mobile medical healthcare service that allows patients to easily manage their own medical information and use it in a variety of ways, including filing insurance claims by directly linking digital medical information at large hospitals such as Seoul National University Hospital, Samsung Seoul Hospital, and Severance Hospital. But also, MediBloc in Korea has successfully launched and is operating “Dr. Palette”, a next-generation EHR solution, and has proven its growth potential as a medical information platform through the connection of these solutions. MediBloc in Korea is being recognized for its technology by actively conducting research and development with 20 foreign and domestic medical institutions and industries. Among these projects, it is conducting KISA work with Harvard Medical School’s training hospital MGH, Seoul National University Hospital, Severance Hospital, and Samsung Seoul Hospital. Additionally, MediBloc has received great attention for its participation in a research consortium invested by KT and the Bill & Melinda Gates Foundation. In particular, in 2018, it was selected as one of the “10 South Korea Startups Powering into 2018”, and it has only expanded its spotlight since then.
